☆ 4.5 Article

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry

INFLAMMATORY BOWEL DISEASES (2021)

Get Full Text
Add to Collection

Journal

INFLAMMATORY BOWEL DISEASES
Volume 27, Issue 4, Pages 585-589

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/ibd/izaa303

Keywords

inflammatory bowel disease; Crohn's disease; ulcerative colitis; coronavirus disease 2019; tofacitinib; outcomes

Categories

Gastroenterology & Hepatology

Funding

  1. Helmsley Charitable Trust [2003-04445]
  2. National Center for Advancing Translational Sciences [UL1TR002489]
  3. Pfizer
  4. Takeda Pharmaceutical Company
  5. Janssen Biotech.
  6. AbbVie Inc.
  7. Eli Lilly and Company
  8. Genentech
  9. Boehringer Ingelheim
  10. Bristol Myers Squibb
  11. Celtrion
  12. Arenapharm
  13. [T32DK007634]
  14. [K23KD111995-01A1]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.